NCT01031355 - Bioequivalence Study: 3 mg Estradiol Valerate (EV) With and Without Levomefolate Calcium | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 31, 2009

Primary Completion Date

February 28, 2010

Study Completion Date

March 31, 2010

Conditions

ContraceptionOvulation Inhibition

Interventions

DRUG

Estradiol Valerate (EV) / Levomefolate Calcium (BAY98-7078)

Oral, single dose, 3 mg EV + 0.451 mg levomefolate calcium, washout phase between treatments: at least 7 days

DRUG

Estradiol Valerate (EV) (BAY86-4980)

Oral, single dose, 3 mg EV, washout phase between treatments: at least 7 days

DRUG

Levomefolate Calcium (BAY86-7660)

Oral, single dose, 0.451 mg levomefolate calcium, washout phase between treatments: at least 7 days

Trial Locations (1)

Neu-Ulm